HealthMore in Health→
Intellia’s Phase 3 Result Marks a Turning Point for In Vivo CRISPR Medicine
Key Takeaways
- Intellia’s in vivo CRISPR therapy reportedly succeeded in a Phase 3 trial.
- The result is described as a first for an in vivo CRISPR treatment.
- The milestone could put the therapy on track for potential FDA approval.
- The outcome is significant for the broader field of gene editing delivered directly inside the body.
DE
DT Editorial Team··via endpoints.news